tiprankstipranks
Advertisement
Advertisement
Ascentage Pharma: Buy Rating Reiterated on Advancing CML/ALL Pipeline and DCF-Supported Unchanged $48 Price Target
PremiumRatingsAscentage Pharma: Buy Rating Reiterated on Advancing CML/ALL Pipeline and DCF-Supported Unchanged $48 Price Target
28d ago
Ascentage Pharma to Present 17 Hematology Clinical Updates at June 2026 EHA Congress
Premium
Company Announcements
Ascentage Pharma to Present 17 Hematology Clinical Updates at June 2026 EHA Congress
29d ago
Ascentage Pharma to Highlight Oncology Portfolio at May–June 2026 Investor Conferences
Premium
Company Announcements
Ascentage Pharma to Highlight Oncology Portfolio at May–June 2026 Investor Conferences
30d ago
Ascentage Pharma initiated with a Buy at BTIG
PremiumThe FlyAscentage Pharma initiated with a Buy at BTIG
3M ago
Ascentage Pharma: Undervalued Long-Term Oncology Leader Backed by Late-Stage Assets Olverembatinib and Lisaftoclax
Premium
Ratings
Ascentage Pharma: Undervalued Long-Term Oncology Leader Backed by Late-Stage Assets Olverembatinib and Lisaftoclax
3M ago
Ascentage Pharma Sets March 25, 2026 Date to Unveil 2025 Unaudited Results and Business Update
Premium
Company Announcements
Ascentage Pharma Sets March 25, 2026 Date to Unveil 2025 Unaudited Results and Business Update
3M ago
Ascentage Pharma Details 2026 Global Innovation Strategy at J.P. Morgan Healthcare Conference
PremiumCompany AnnouncementsAscentage Pharma Details 2026 Global Innovation Strategy at J.P. Morgan Healthcare Conference
5M ago
Ascentage Pharma initiated with a Buy at Rodman & Renshaw
Premium
The Fly
Ascentage Pharma initiated with a Buy at Rodman & Renshaw
5M ago
Ascentage Pharma Wins FDA IND Clearance for BTK Degrader APG-3288 to Enter Global Phase I Trial
Premium
Company Announcements
Ascentage Pharma Wins FDA IND Clearance for BTK Degrader APG-3288 to Enter Global Phase I Trial
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100